Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are ...

As a third-generation EGFR inhibitor, Yuhan-partnered Lazcluze ... occurred in 40% of patients who took the new therapy compared with 11% in the control group. Thanks to the addition of Rybrevant ...

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Scientists have discovered a new weakness in lung cancer that could lead to better treatments and help prevent the disease ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

The breadth of data at ELCC reinforce TAGRISSO as the backbone therapy for patients with this disease and show that adding savolitinib or datopotamab deruxtecan-dlnk at the time of disease ...

US-based biopharmaceutical company Hoth Therapeutics has reported interim data from a Phase IIa trial of HT-001, a drug ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...